Literature DB >> 25557247

PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation.

Boram Min1, Young-Chang Kwon, Kwang-Min Choe, Kwang Chul Chung.   

Abstract

Parkinson's disease (PD) is characterized by progressive dopaminergic neuronal loss and the formation of abnormal protein aggregates, referred to as Lewy bodies (LBs). PINK1 is a serine/threonine protein kinase that protects cells from stress-induced mitochondrial dysfunction. PINK1 gene mutations cause one form of autosomal recessive early-onset PD. Transglutaminase 2 (TG2) is an intracellular protein cross-linking enzyme that has an important role in LB formation during PD pathogenesis. This study identifies PINK1 as a novel TG2 binding partner and shows that PINK1 stabilizes the half-life of TG2 via inhibition of TG2 ubiquitination and subsequent proteasomal degradation. PINK1 affects TG2 stability in a kinase-dependent manner. In addition, PINK1 directly phosphorylates TG2 in carbonyl cyanide m-chlorophenyl hydrazine-induced mitochondrial damaged states, thereby enhancing TG2 accumulation and intracellular protein cross-linking products. This study further confirms the functional link between upstream PINK1 and downstream TG2 in Drosophila melanogaster. These data suggest that PINK1 positively regulates TG2 activity, which may be closely associated with aggresome formation in neuronal cells.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  PINK1; Parkinson's disease; phosphorylation; transglutaminase 2; ubiquitination

Mesh:

Substances:

Year:  2014        PMID: 25557247     DOI: 10.1002/jnr.23535

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  5 in total

1.  Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin.

Authors:  Eunju Im; Lang Yoo; Minju Hyun; Woo Hyun Shin; Kwang Chul Chung
Journal:  Open Biol       Date:  2016-08       Impact factor: 6.411

Review 2.  New insight into transglutaminase 2 and link to neurodegenerative diseases.

Authors:  Boram Min; Kwang Chul Chung
Journal:  BMB Rep       Date:  2018-01       Impact factor: 4.778

3.  Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein.

Authors:  André D G Leitão; Paulina Rudolffi-Soto; Alexandre Chappard; Akshay Bhumkar; Derrick Lau; Dominic J B Hunter; Yann Gambin; Emma Sierecki
Journal:  Commun Biol       Date:  2021-09-23

4.  Pre-clinical Studies Identifying Molecular Pathways of Neuroinflammation in Parkinson's Disease: A Systematic Review.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Mohammad Sadegh Qadirifard; Mohammadreza Kosari; Navid Naghsh; Afsaneh Asgari Taei; Andis Klegeris; Mina Dehghani; Ashkan Bahrami; Hamed Taheri; Ashraf Mohamadkhani; Ramtin Hajibeygi; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Aging Neurosci       Date:  2022-07-04       Impact factor: 5.702

Review 5.  Current Experimental Studies of Gene Therapy in Parkinson's Disease.

Authors:  Jing-Ya Lin; Cheng-Long Xie; Su-Fang Zhang; Weien Yuan; Zhen-Guo Liu
Journal:  Front Aging Neurosci       Date:  2017-05-03       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.